John P. Murad

1.7k total citations
22 papers, 1.1k citations indexed

About

John P. Murad is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Immunology. According to data from OpenAlex, John P. Murad has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 5 papers in Cardiology and Cardiovascular Medicine and 5 papers in Immunology. Recurrent topics in John P. Murad's work include CAR-T cell therapy research (12 papers), Immunotherapy and Immune Responses (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (5 papers). John P. Murad is often cited by papers focused on CAR-T cell therapy research (12 papers), Immunotherapy and Immune Responses (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (5 papers). John P. Murad collaborates with scholars based in United States, United Kingdom and Poland. John P. Murad's co-authors include Saul J. Priceman, Wen-Chung Chang, Stephen J. Forman, Anthony K. Park, Fadi T. Khasawneh, Brook Jeang, Dileshni Tilakawardane, Jason Yang, Christine E. Brown and Harold J. Ting and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

John P. Murad

20 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John P. Murad United States 12 783 341 326 303 265 22 1.1k
Su Yan United States 9 755 1.0× 378 1.1× 235 0.7× 349 1.2× 196 0.7× 12 1.0k
Jessica Wagner United States 12 408 0.5× 213 0.6× 104 0.3× 344 1.1× 67 0.3× 24 751
Valeria Giandomenico Sweden 23 724 0.9× 229 0.7× 70 0.2× 578 1.9× 195 0.7× 40 1.4k
Mahdi Abdoli Shadbad Iran 22 569 0.7× 454 1.3× 110 0.3× 558 1.8× 64 0.2× 60 1.3k
Fabien Franco Switzerland 12 738 0.9× 1.1k 3.3× 114 0.3× 659 2.2× 84 0.3× 14 1.9k
Lijun Zhao China 14 406 0.5× 226 0.7× 86 0.3× 319 1.1× 77 0.3× 22 837
Zhiyu Li China 14 372 0.5× 231 0.7× 80 0.2× 368 1.2× 58 0.2× 25 880
Yibing Xu China 15 401 0.5× 425 1.2× 95 0.3× 438 1.4× 53 0.2× 26 1.0k
Heng Sun China 14 228 0.3× 81 0.2× 159 0.5× 331 1.1× 45 0.2× 25 740
Roberto Arriga Italy 15 318 0.4× 257 0.8× 70 0.2× 217 0.7× 41 0.2× 24 656

Countries citing papers authored by John P. Murad

Since Specialization
Citations

This map shows the geographic impact of John P. Murad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John P. Murad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John P. Murad more than expected).

Fields of papers citing papers by John P. Murad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John P. Murad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John P. Murad. The network helps show where John P. Murad may publish in the future.

Co-authorship network of co-authors of John P. Murad

This figure shows the co-authorship network connecting the top 25 collaborators of John P. Murad. A scholar is included among the top collaborators of John P. Murad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John P. Murad. John P. Murad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Anthony K., Isabel Monroy, Yuwei Ren, et al.. (2025). Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011051–e011051.
2.
Murad, John P., Yuwei Ren, Anthony K. Park, et al.. (2025). Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nature Biomedical Engineering. 2 indexed citations
3.
Murad, John P., Yukiko Yamaguchi, Ching Ouyang, et al.. (2024). Abstract 6676: Microbiome modification impacts PSCA directed chimeric antigen receptor (CAR) T cell therapy for prostate cancer. Cancer Research. 84(6_Supplement). 6676–6676.
4.
Yamaguchi, Yukiko, Ethan Gerdts, Brook Jeang, et al.. (2024). Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells. SHILAP Revista de lepidopterología. 32(2). 200789–200789. 4 indexed citations
5.
Murad, John P., Dileshni Tilakawardane, Anthony K. Park, et al.. (2021). Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Molecular Therapy. 29(7). 2335–2349. 72 indexed citations
6.
Phuengkham, Hathaichanok, Lena Gamboa, Jason Yang, et al.. (2021). Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nature Biomedical Engineering. 5(11). 1348–1359. 110 indexed citations
7.
Murad, John P., Anna Kozłowska, Hee Jun Lee, et al.. (2018). Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Frontiers in Immunology. 9. 2268–2268. 100 indexed citations
8.
Priceman, Saul J., Ethan Gerdts, Dileshni Tilakawardane, et al.. (2017). Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. OncoImmunology. 7(2). e1380764–e1380764. 120 indexed citations
9.
Priceman, Saul J., Dileshni Tilakawardane, Brook Jeang, et al.. (2017). Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clinical Cancer Research. 24(1). 95–105. 249 indexed citations
10.
Chung, Brile, John P. Murad, Emily S. Andersen, et al.. (2017). Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12. npj Breast Cancer. 3(1). 6–6. 63 indexed citations
11.
Murad, John P., Dileshni Tilakawardane, Brenda Aguilar, et al.. (2016). 204. HER2-Specific Chimeric Antigen Receptor T Cells for the Treatment of Breast-to-Brain Metastasis. Molecular Therapy. 24. S79–S80. 1 indexed citations
12.
Chung, Brile, Tor B. Stuge, John P. Murad, et al.. (2014). Antigen-Specific Inhibition of High-Avidity T Cell Target Lysis by Low-Avidity T Cells via Trogocytosis. Cell Reports. 8(3). 871–882. 20 indexed citations
13.
Murad, John P., et al.. (2012). A novel antibody targeting the ligand binding domain of the thromboxane A2 receptor exhibits antithrombotic properties in vivo. Biochemical and Biophysical Research Communications. 421(3). 456–461. 10 indexed citations
14.
Murad, John P., et al.. (2012). Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions. Current Molecular Medicine. 13(1). 165–178. 12 indexed citations
15.
Murad, John P., et al.. (2011). The C-terminal segment of the second extracellular loop of the thromboxane A2 receptor plays an important role in platelet aggregation. Biochemical Pharmacology. 83(1). 88–96. 7 indexed citations
16.
Murad, John P., Harold J. Ting, & Fadi T. Khasawneh. (2011). A Novel Mechanism for Calcium Entry Into Blood Platelets. The FASEB Journal. 25(S1). 1 indexed citations
17.
Murad, John P., et al.. (2011). Mouse transient receptor potential channel 6: Role in hemostasis and thrombogenesis. Biochemical and Biophysical Research Communications. 417(2). 853–856. 30 indexed citations
18.
Murad, John P., et al.. (2011). Characterization of theIn VivoAntiplatelet Activity of the Antihypertensive Agent Losartan. Journal of Cardiovascular Pharmacology and Therapeutics. 17(3). 308–314. 9 indexed citations
19.
Murad, John P., et al.. (2011). Aspirin: Pharmacology and Clinical Applications. PubMed. 2012. 1–15. 61 indexed citations
20.
Cheymol, J, et al.. (1960). [Contribution to the chemical and pharmacological study of derivatives of orthophosphoric acid. III. Chemical composition and anticholinesterase activity].. PubMed. 15. 237–41. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Su Yan Breakdown of academic impact, for papers by Jessica Wagner Breakdown of academic impact, for papers by Valeria Giandomenico Breakdown of academic impact, for papers by Mahdi Abdoli Shadbad Breakdown of academic impact, for papers by Fabien Franco Breakdown of academic impact, for papers by Lijun Zhao Breakdown of academic impact, for papers by Zhiyu Li Breakdown of academic impact, for papers by Yibing Xu Breakdown of academic impact, for papers by Heng Sun Breakdown of academic impact, for papers by Roberto Arriga
Rankless by CCL
2026